



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

8 April 2026  
EMA/68264/2026  
Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 23-26 March 2026

During its March 2026 meeting, the CHMP reviewed 5 recommendations for eligibility to PRIME: 3 were granted and 2 were denied. The individual outcomes adopted this month are listed below.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



## Eligibility granted

| Name*                   | Product type                       | Therapeutic area                                | Therapeutic indication   | Type of data supporting request     | Type of applicant |
|-------------------------|------------------------------------|---|--|-------------------------------------|-------------------|
| Rapcabtagene autoleucel | Advanced Therapy Medicinal Product | Musculoskeletal and connective tissue disorders | Treatment of severe refractory idiopathic inflammatory myopathies              | Non-clinical + clinical exploratory | Other             |
| Puliretgene parvec      | Advanced Therapy Medicinal Product | Eye disorders                                   | Treatment of inherited retinal dystrophy due to dysfunction in the CYP4V2-gene | Non-clinical + clinical exploratory | Other             |
| Privosegtor             | Chemical Medicinal Product         | Eye disorders                                   | Treatment of optic neuritis  | Non-clinical + clinical exploratory | SME               |

\* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.


## Eligibility denied

| Product type                       | Therapeutic area        | Therapeutic indication   | Type of data supporting request     | Type of applicant |
|------------------------------------|-------------------------|--|-------------------------------------|-------------------|
| Advanced Therapy Medicinal Product | Immune system disorders | Treatment of Systemic Lupus (with or without Nephritis) refractory to standard therapy   | Non-clinical + clinical exploratory | Other             |
| Biological Medicinal Product       | Oncology                | Treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, in patients who have received prior bevacizumab and mirvetuximab soravtansine, if eligible | Non-clinical + clinical exploratory | Other             |

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## Cumulative overview of PRIME eligibility recommendations adopted by 26 March 2026

■ Granted   
 ■ Denied   
 ■ Out of scope\*   
 ■ Withdrawn



\* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.